Compare TTMI & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | ELAN |
|---|---|---|
| Founded | 1978 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.2B |
| IPO Year | 2000 | 2018 |
| Metric | TTMI | ELAN |
|---|---|---|
| Price | $135.70 | $22.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $203.00 | $31.00 |
| AVG Volume (30 Days) | 1.6M | ★ 4.2M |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 211.11 | N/A |
| EPS | ★ 1.24 | 0.22 |
| Revenue | $2,906,345,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $51.16 | $8.66 |
| Revenue Next Year | $23.81 | $5.29 |
| P/E Ratio | $102.02 | ★ $98.95 |
| Revenue Growth | ★ 18.98 | 6.22 |
| 52 Week Low | $53.36 | $19.40 |
| 52 Week High | $223.83 | $27.98 |
| Indicator | TTMI | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 46.06 |
| Support Level | $87.36 | $21.89 |
| Resistance Level | $150.07 | $25.21 |
| Average True Range (ATR) | 6.58 | 0.72 |
| MACD | 1.52 | -0.00 |
| Stochastic Oscillator | 91.48 | 51.49 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.